GT Biopharma is trading 6.67% up at $0.32 in pre-market, with no new company-specific announcement identified for August 31, 2026 and the catalyst unclear.
- Its latest significant disclosure was the August 14, 2026 second-quarter report.
- The report discussed clinical-trial progress and approximately $5.1 million in cash.
- The broader market is mixed, and the move may reflect thin pre-market trading.